Figures & data
Figure 1. Intratumoral CD4+ T cells functional alterations during melanoma progression and PLX4720 therapy. Tumor-infiltrating CD4+ T cells lose the expression of interferon γ (IFNγ) and CD40L during tumor growth accompanied by accumulation of Tregs, MDSCs and immature APCs (TAMs and TIDCs). Treating tumor-bearing mice with PLX4720 stimulated the expression of IFNγ and CD40L on intratumoral CD4+ T cells. Thus, PLX4720 treatment promotes the immunostimulatory properties of the tumor microenvironment and suppress the accumulation of Tregs and MDSCs. Tregs, regulatory T cells; MDSCs, myeloid-derived suppressor cells; APCs, antigen-presenting cells; TAMs, tumor-associated macrophages; TIDCs, tumor-infiltrating dendritic cells.
